Search results
Pfizer stock price analysis: how PFE became a fallen angel | Invezz
Invezz· 21 hours agoPfizer (NYSE: PFE) stock price has crashed hard in the past few years as demand for Covid-19...
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb
Motley Fool via Yahoo Finance· 18 hours agoPfizer's slightly higher dividend yield and broad pipeline give it the edge in this comparison. That...
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
Zacks via Yahoo Finance· 11 hours agoInvestors should also take note of any recent adjustments to analyst estimates for Pfizer. Such...
Cantor Fitzgerald Reiterates “Overweight” Rating for Pfizer (NYSE:PFE)
ETF DAILY NEWS· 6 hours agoCantor Fitzgerald’s price target indicates a potential upside of 64.17% from the stock’s previous close. Morgan Stanley upped their target price ...
Pfizer (NYSE:PFE) Stock Price Down 0.9%
ETF DAILY NEWS· 4 days agoPfizer Inc. (NYSE:PFE – Get Free Report) was down 0.9% during trading on Thursday . The company traded as low as $27.20 and last traded at $27.41. Approximately 11,513,196 ...
Pfizer Inc. (NYSE:PFE) Shares Sold by B. Riley Wealth Advisors Inc.
ETF DAILY NEWS· 21 hours agoB. Riley Wealth Advisors Inc. decreased its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 15.0% during the fourth quarter, according to its most recent 13F ...
Pfizer Inc. (NYSE:PFE) Shares Sold by CoreFirst Bank & Trust
ETF DAILY NEWS· 21 hours agoThe fund owned 42,156 shares of the biopharmaceutical company’s stock after selling 1,011 shares during the period. CoreFirst Bank & Trust’s holdings in Pfizer< ...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 6 days agoBenefits For Regenxbio, Solid But most analysts didn't consider Pfizer a serious competitor. "The...
Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors
Zacks via Yahoo Finance· 6 days agoPfizer (PFE) closed the latest trading day at $27.66, indicating a -1.32% change from the previous...
Pfizer's gene-therapy trial failure boosts Sarepta's stock
Morningstar· 6 days agoShares of Sarepta Therapeutics Inc. (SRPT) gained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a late-stage trial. Pfizer Inc. said ...